Article Text

Download PDFPDF

Cancer research in the era of immunogenomics
  1. Yochai Wolf,
  2. Yardena Samuels
  1. Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
  1. Correspondence to Professor Yardena Samuels; Yardena.samuels{at}weizmann.ac.il

Abstract

The most meaningful advancement in cancer treatment in recent years has been the emergence of immunotherapy. Checkpoint inhibitor blockade and adoptive T cell therapy have shown remarkable clinical effects in a wide range of tumour types. Despite these advances, many tumours do not respond to these treatments, which raises the need to further investigate how patients can benefit from immunotherapy. This effort can now take advantage of the recent technological progress in single-cell, high-throughput sequencing and computational efforts. In this review, we will discuss advances in different immunotherapies and the principles of cancer immunogenomics, with an emphasis on the detection of cancer neoantigens with human leucocyte antigen peptidomics, and how these principles can be further used for more efficient clinical output.

  • immunogenomics

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors All authors contributed equally.

  • Funding YS is supported by the Israel Science Foundation grant number 696/17, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 754282), the ERC (CoG- 770854), the MRA (#402024), The Rising Tide Foundation, the Minerva Foundation Grant, the Knell Family and the Hamburger Family.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.